Oph All News Today

The panel discusses disparities in the quality of care received by Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients.

Insights on real-world ponatinib treatment strategies and safety in Philadelphia-positive acute lymphoblastic leukemia are provided by Hagop Kantarjian, MD, and Bijal D. Shah, MD, MS.

Bijal Shah, MD, MS, and Hagop Kantarjian, MD, discuss promising results and regulatory progress for ponatinib in frontline Philadelphia-positive acute lymphoblastic leukemia treatment.

Key opinion leaders review the evolution of Ph+ ALL treatment, from Hyper-CVAD to novel TKIs, blinatumomab, and deintensification, improving remission rates and survival.

Expert Elias Jabbour, MD, reviews clinical data from the PhALLCON study of ponatinib vs imatinib in patients with Ph+ acute lymphocytic leukemia and considers its clinical implications.